World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
59
Citations
28343
World Ranking
3373
National Ranking
1557

Christopher A. Klebanoff publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Christopher A. Klebanoff sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 123 publications — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Christopher A. Klebanoff D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Christopher A. Klebanoff sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 59 D-Index — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Christopher A. Klebanoff is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on the fields of Medicine, Immunology and Microbiology, and Biochemistry, Genetics and Molecular Biology.

The subfields of study within their work include Oncology, Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Genetics.

Research topics frequently addressed by Klebanoff encompass CAR-T cell therapy research, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, Monoclonal and Polyclonal Antibodies Research, T-cell and B-cell Immunology, and Virus-based gene therapy research.

The scientist has authored numerous papers, including:

  • Clinical implications of T cell exhaustion for cancer immunotherapy, 2022, Nature Reviews Clinical Oncology
  • T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome, 2023, Nature Reviews Drug Discovery
  • Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA, 2022, Nature Medicine
  • The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer, 2022, Immunity
  • Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study, 2020, Clinical Cancer Research

Klebanoff frequently collaborates with several authors including Smita S. Chandran, Iñaki Etxeberría, Michael V. Gormally, Darwin Kwok, and Nicholas Stevers.

The scientist has published extensively in a variety of venues, notably Cancer Research, bioRxiv (Cold Spring Harbor Laboratory), Regular and Young Investigator Award Abstracts, Cancer Immunology Research, and Journal of Clinical Oncology.

Best Publications

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

    Luca Gattinoni;Steven E. Finkelstein;Christopher A. Klebanoff;Christopher A. Klebanoff;Paul A. Antony

  • Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

    Christopher A. Klebanoff;Luca Gattinoni;Parizad Torabi-Parizi;Keith Kerstann

  • Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

    Luca Gattinoni;Christopher A. Klebanoff;Christopher A. Klebanoff;Douglas C. Palmer;Claudia Wrzesinski

  • Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells

    Willem W. Overwijk;Marc R. Theoret;Steven E. Finkelstein;Deborah R. Surman

  • TOX is a critical regulator of tumour-specific T cell differentiation

    Andrew C Scott;Andrew C Scott;Friederike Dündar;Paul Zumbo;Smita S Chandran

  • Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function

    Madhusudhanan Sukumar;Jie Liu;Yun Ji;Murugan Subramanian

  • CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4 T helper cells and hindered by naturally occurring T regulatory cells.

    Paul A. Antony;Ciriaco A. Piccirillo;Akgül Akpinarli;Steven E. Finkelstein

  • Clinical implications of T cell exhaustion for cancer immunotherapy

    Unknown

  • IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells

    Christopher A. Klebanoff;Steven E. Finkelstein;Deborah R. Surman;Michael K. Lichtman;Michael K. Lichtman

  • Ionic immune suppression within the tumour microenvironment limits T cell effector function

    Robert Eil;Suman K. Vodnala;David Clever;Christopher A. Klebanoff;Christopher A. Klebanoff

  • Paths to stemness: building the ultimate antitumour T cell

    Luca Gattinoni;Christopher A. Klebanoff;Nicholas P. Restifo

  • CD8+ T‐cell memory in tumor immunology and immunotherapy

    Christopher A. Klebanoff;Luca Gattinoni;Nicholas P. Restifo

  • Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

    James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;Victoria Shi

  • Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy

    Christopher A. Klebanoff;Hung T. Khong;Paul A. Antony;Douglas C. Palmer

  • IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

    Christian S. Hinrichs;Rosanne Spolski;Chrystal M. Paulos;Luca Gattinoni

  • T cell stemness and dysfunction in tumors are triggered by a common mechanism.

    Suman Kumar Vodnala;Robert Eil;Rigel J. Kishton;Madhusudhanan Sukumar

  • Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature

    Pawel Muranski;Zachary A. Borman;Sid P. Kerkar;Christopher A. Klebanoff

  • BACH2 represses effector programs to stabilize T reg -mediated immune homeostasis

    Rahul Roychoudhuri;Kiyoshi Hirahara;Kiyoshi Hirahara;Kambiz Mousavi;David Clever

  • Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

    Stephanie L. Goff;Mark E. Dudley;Deborah E. Citrin;Robert P. Somerville

  • Prospects for gene-engineered T cell immunotherapy for solid cancers.

    Christopher A Klebanoff;Steven A Rosenberg;Nicholas P Restifo

Frequent Co-Authors

Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Luca Gattinoni
Luca Gattinoni University of Regensburg
Douglas C. Palmer
Douglas C. Palmer National Institutes of Health
Zhiya Yu
Zhiya Yu National Institutes of Health
Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
David A. Scheinberg
David A. Scheinberg Memorial Sloan Kettering Cancer Center
Ena Wang
Ena Wang Toro bio
Paul F. Robbins
Paul F. Robbins National Cancer Institute
Richard M. Siegel
Richard M. Siegel National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can offer practical career pathways. Many students begin with foundational programs like the easiest absn to get into, which provide a streamlined route into nursing while building critical patient care skills.

Nursing support roles are also vital, and enrolling in accredited lpn programs easy to get into can be a manageable entry point. These programs prepare students for hands-on roles essential to clinical environments where immunology expertise is applied.

For advanced practice, the easiest nurse practitioner program options offer a flexible route to higher responsibilities in patient diagnosis and treatment, often integrating immunology-related knowledge.

Additionally, specializing in mental health through pmhnp programs online with best clinical placement ensures excellent practical experience alongside theoretical learning, crucial for those interested in the immunological impacts of mental health disorders.

Exploring these pathways helps align your education with the dynamic field of immunology and healthcare, providing diverse opportunities to make a meaningful impact.

Best Scientists Citing Christopher A. Klebanoff

Trending Scientists

Recently Published Articles